PMEL and neoplasm: Furthermore, when activated T cells from Pmel TCR transgenic mice (whose TCR are specific for the gp100 antigen expressed by B16F1cOVA) were transferred 24 hours following FUS+MBs treatment of B16F1cOVA and harvested 5 hours later, we found no differences in the number of activated Pmel or non-specific T cells in the tumor or meninges (Figure S7).